Top

Published in:

01-11-2014 | Original Article

Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms

Authors: Jarmila Kissova, Alena Bulikova, Petra Ovesna, Ludmila Bourkova, Miroslav Penka

Published in: International Journal of Hematology | Issue 5/2014

Abstract

BCR/ABL-negative myeloproliferative neoplasms (MPNs) are considered to be acquired thrombophilic conditions. Persistently enhanced platelet activation has been described in polycythaemia vera and essential thrombocythaemia (ET), and shown to contribute to a higher risk of arterial and venous thrombotic complications. Recent studies have shown that mean platelet volume (MPV) and immature platelet fraction (IPF) can serve as useful markers of platelet activation and increased risk of thrombosis. The aim of the present study was to investigate the relationship between these parameters and thrombotic events in BCR/ABL-negative MPN. MPV values in patients with BCR/ABL-negative MPN were significantly higher than MPV values of healthy individuals (P < 0.001). No significant difference in MPV or IPF was observed between groups of patients with and without thrombotic complications (P = 0.441; P = 0.110); the difference in IPF values was close to the significance level for patients with ET (P = 0.073). Higher values of IPF were more frequently detected in patients with JAK2 V617F positivity (P = 0.030). These patients had higher MPV more frequently than others, and this difference was close to the significance level (P = 0.056). Further studies should validate the use of platelet parameters to identify patients at high risk.

Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, Mazzucconi MG, Rodeghiero F, Tura S. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89:215–32.PubMed

Tefferi A, Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Rev. 2001;15:121–31.PubMedCrossRef

Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117:755–61.PubMedCrossRef

Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224–32.PubMedCrossRef

Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, Van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR. United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33–45.PubMedCrossRef

Elliot MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128:275–90.CrossRef

Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M, Manarini S, Finazzi G, Cerletti C, Barbui T. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood. 2000;96:4261–6.PubMed

Arellano RE, Alvarez LA, Reverter JC, Colomer D, Villamor N, Bellosillo B, Cervantes F. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol. 2009;84:102–8.CrossRef

Falanga A, Russo L, Marchetti M. Mechanisms of thrombogenesis. In: Barbui T, Tefferi A, editors. Myeloproliferative neoplasms. Springer- Verlag: Berlin Heidelberg; 2012. p. 57–67.CrossRef

10.

Harrison CN (2005) Platelets and thrombosis in myeloproliferative diseases. Hematology Am Soc Hematol Educ Program 409–15.

11.

Michiels JJ, Berneman Z, Van Bockstaele D, Van der Planken M, De RH, Schroyens W. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost. 2006;32:174–207.PubMedCrossRef

12.

Arellano RE, Alvarez LA, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006;91:169–75.

13.

Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol. 2005;33:523–30.PubMedCrossRef

14.

Jensen MK, Nully BP, Lund BV, Nielsen OJ, Hasselbach HC. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol. 2000;110:116–24.PubMedCrossRef

15.

Kamath S, Blann AD, Lip GY. Platelet activation: assessment and quantification. Eur Heart J. 2001;22:1561–71.PubMedCrossRef

16.

Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis. 1996;7:157–61.PubMedCrossRef

17.

Slavka G, Perkmann T, Haslacher H, Greisenegger S, Marsik C, Wagner OF, Endler G. Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease. Arterioscler Thromb Vasc Biol. 2001;31:1215–8.CrossRef

18.

Berger JS, Eraso LH, Xie D, Sha D, Mohler ER. Mean platelet volume and prevalence of peripheral artery disease, the National Health and Nutrition Examination Survey, 1999-2004. Atherosclerosis. 2010;213:586–91.PubMedCentralPubMedCrossRef

19.

Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, Mohler ER, Reilly MP, Berger JS. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. Thromb Heamost. 2010;8:148–56.CrossRef

20.

Endler G, Klimesch A, Sunder PH, Schillinger M, Exner M, Mannhalter C, Jordanova N, Christ G, Thalhammer R, Huber K, Sunder PR. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol. 2002;117:399–404.PubMedCrossRef

21.

Bath P, Algert C, Chapman N, Neal B. Progress Collaborative Group: association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke. 2004;5:622–6.CrossRef

22.

Braekkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Størmer J, Hansen JB. Mean platelet volume is a risk factor for venous thromboembolism: the Tromsø Study, Tromsø, Norway. J Thromb Haemost. 2010;8:157–62.PubMedCrossRef

23.

Ingram M, Coopersmith A. Reticulated platelets following acute blood loss. Br J Haematol. 1969;7:225–9.CrossRef

24.

Cesari F, Marcucci R, Caporale R, Paniccia R, Romano E, Gensini GF, Abbate R, Gori AM. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost. 2008;99:930–5.PubMed

25.

Cesari F, Marcucci R, Gori AM, Caporale R, Fanelli A, Casola G, Balzi D, Barchielli A, Valente S, Giglioli C, Gensini GF, Abbate R. Reticulated platelets predict cardiovascular death in acute coronary syndrome patients. Insights from the AMI-Florence 2 Study. Thromb Haemost. 2013;109:846–53.PubMedCrossRef

26.

Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost. 2009;101:151–6.PubMed

27.

Nakamura T, Uchiyama S, Yamazaki M, Okubo K, Takakuwa Y, Iwata M. Flow cytometric analysis of reticulated platelets in patients with ischemic stroke. Thromb Res. 2002;106:171–7.PubMedCrossRef

28.

Würtz M, Grove EL, Wulff LN, Kaltoft AK, Tilsted HH, Jensen LO, Hvas AM, Kristensen SD. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. JACC Cardiovasc Interv. 2010;3:828–35.PubMedCrossRef

29.

Biggs C, Kunka S, Hart D, Oguni S, Machin SJ. Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia. Br J Haematol. 2004;126:93–9.CrossRef

30.

Falanga A, Marchetti M (2012) Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program p. 571–81.

31.

Diquattro M, Gagliano F, Calabró GM, Tammasi M, Scott CS, Mancuso G, Palma B, Menozzi I. Relationships between platelet counts, platelet volumes and reticulated platelets in patients with ITP: evidence for significant platelet count inaccuracies with conventional instrument methods. Int J Lab Hematol. 2009;31:199–206.PubMedCrossRef

32.

Landolfi R, Ciabattoni G, Patrignani P, Castellana MA, Pogliani E, Bizzi B, Patrono C. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin- suppressible platelet activation in vivo. Blood. 1992;80:1965–71.PubMed

33.

Arellano RE, Alvaréz LA, Reverter JC, Vilamor N, Jou JM, Cervantes F. Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemia. Platelets. 2012;23:336–43.CrossRef

34.

Panova NM, Marchetti M, Buoro S, Russo L, Leuzzi A, Finazzi G, Rambaldi A, Ottomano C, Ten CH, Falanga A. JAK2 V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood. 2011;118:2599–601.CrossRef

35.

Thompson CB, Jakubowski JA, Quinn PG, Deykin D, Valeri CR. Platelet size and age determine platelet function independently. Blood. 1984;63:1372–5.PubMed

36.

Bessman JD, Williams LJ, Gilmer PR Jr. Mean platelet volume. The inverse relation of platelet size and count in normal subjects, and an artifact of other particles. Am J Clin Pathol. 1981;76:289–93.PubMed

37.

Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Vougarelis M. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res. 2009;33:67–73.PubMedCrossRef

38.

Hobbs CM, Manning H, Bennett C, Vasquez L, Severin S, Brain L, Mazharian A, Guerrero JA, Li J, Soranzo N, Green AR, Watson SP, Ghevaer C. JAK2 V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood. 2013;122:3787–97.PubMedCentralPubMedCrossRef

39.

Martin J. The relationship between megakaryocyte ploidy and platelet volume. Blood Cells. 1989;15:108–21.PubMed

Title: Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms
Authors: Jarmila Kissova
Alena Bulikova
Petra Ovesna
Ludmila Bourkova
Miroslav Penka
Publication date: 01-11-2014
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 5/2014
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-014-1673-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2014

Clostridium difficile infection: an undeniably common problem among hematopoietic transplant recipients

A regulatory network governing Gata1 and Gata2 gene transcription orchestrates erythroid lineage differentiation

Cytogenetics and clinical features of pediatric myelodysplastic syndrome in Japan

Clinicopathological and molecular features of myeloid sarcoma as initial presentation of therapy-related myeloid neoplasms: a single institution experience

Refractory autoimmune hemolytic anemia in a patient with DiGeorge syndrome treated successfully with plasma exchange: a case report and review of the literature

Elevated soluble platelet glycoprotein VI is a useful marker for DVT in postoperative patients treated with edoxaban

Keynote webinar | Spotlight on antibody–drug conjugates in cancer